Difference between revisions of "Aclarubicin (Aclacinon)"
m |
Warner-admin (talk | contribs) m (Text replacement - "Category:Intravenous chemotherapy" to "Category:Intravenous medications") |
||
| Line 17: | Line 17: | ||
[[Category:Drug index]] | [[Category:Drug index]] | ||
[[Category:Chemotherapy]] | [[Category:Chemotherapy]] | ||
| − | [[Category:Intravenous | + | [[Category:Intravenous medications]] |
[[Category:Anthracyclines]] | [[Category:Anthracyclines]] | ||
[[Category:Topoisomerase inhibitors]] | [[Category:Topoisomerase inhibitors]] | ||
Revision as of 17:23, 25 July 2017
General information
Class/mechanism: anthracycline and topoisomerase II inhibitor. Not approved by the FDA. Produced by Streptomyces galilaeus.[1]
Route: IV
Extravasation: irritant
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.
Patient drug information
No information available.
Also known as
Aclarubicin hydrochloride, Aclarubicine, ACLA, Aclacinon, Aclaplastin; 75443-99-1, Aclacinomycin A hydrochloride, Aclarubicine A, Aclarubicina clorhidrato, Aclamycine, Aclarubicin Lianhuan